Back to Search
Start Over
Overcoming Doxorubicin Resistance with Lipid–Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide
- Source :
- Molecular Pharmaceutics. 17:2135-2144
- Publication Year :
- 2020
- Publisher :
- American Chemical Society (ACS), 2020.
-
Abstract
- We report on tailored lipid-polymer hybrid nanoparticles (NPs) delivering nitric oxide (NO) under the control of visible light as a tool for overcoming doxorubicin (DOX) resistance. The NPs consist of a polymeric core and a coating. They are appropriately designed to entrap DOX in the poly(lactide-co-glycolide) core and a NO photodonor (NOPD) in the phospholipid shell to avoid their mutual interaction both in the ground and excited states. The characteristic red fluorescence of DOX, useful for its tracking in cells, is well preserved upon incorporation within the NPs, even in the copresence of NOPD. The NP scaffold enhances the NO photoreleasing efficiency of the entrapped NOPD when compared with that of the free compound, and the copresence of DOX does not significantly affect such enhanced photochemical performance. Besides, the delivery of DOX and NOPD from NPs is also not mutually influenced. Experiments carried out in M14 DOX-resistant melanoma cells demonstrate that NO release from the multicargo NPs can be finely regulated by excitation with visible light, at a concentration level below the cytotoxic doses but sufficient enough to inhibit the efflux transporters mostly responsible for DOX cellular extrusion. This results in increased cellular retention of DOX with consequent enhancement of its antitumor activity. This approach, in principle, is not dependent on the type of chemotherapeutic used and may pave the way for new treatment modalities based on the photoregulated release of NO to overcome the multidrug resistance phenomenon and improve cancer chemotherapies.
- Subjects :
- Cell Survival
Polymers
Immunoblotting
Phospholipid
Pharmaceutical Science
Nanoparticle
02 engineering and technology
Nitric Oxide
030226 pharmacology & pharmacy
Nitric oxide
03 medical and health sciences
chemistry.chemical_compound
Drug Delivery Systems
0302 clinical medicine
multidrug resistance
Cell Line, Tumor
Drug Discovery
polycyclic compounds
medicine
Humans
Doxorubicin
Cellular retention
Antitumor activity
chemistry.chemical_classification
Drug Carriers
Antibiotics, Antineoplastic
nanoparticle
technology, industry, and agriculture
Polymer
021001 nanoscience & nanotechnology
Drug Resistance, Multiple
Microscopy, Fluorescence
chemistry
Drug Resistance, Neoplasm
Biophysics
Nanoparticles
Molecular Medicine
DOXORUBICIN RESISTANCE
light
0210 nano-technology
doxorubicin
nanoparticles
nitric oxide
medicine.drug
Subjects
Details
- ISSN :
- 15438392 and 15438384
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Molecular Pharmaceutics
- Accession number :
- edsair.doi.dedup.....4f43b33a1a5742e0cb6166c05a487579